ロード中...
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
PURPOSE: Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscorin...
保存先:
| 出版年: | J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8260909/ https://ncbi.nlm.nih.gov/pubmed/33449816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01086 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|